Showing results (651-660 of 1,179) with videos related to

Sort By:
Pageof 118
The Journal of Biological Chemistry|February 6, 2021
Multiple variants of the fungal effector AVR-Pik bind the HMA domain of the rice protein OsHIPP19, providing a foundation to engineer plant defenseJosephine H R Maidment, Marina Franceschetti, Abbas Maqbool, et al.
Microbiome|February 17, 2019
Genome-resolved metagenomics of eukaryotic populations during early colonization of premature infants and in hospital roomsMatthew R Olm, Patrick T West, Brandon Brooks, et al.
Contemporary Clinical Trials Communications|August 7, 2019
Evaluation of the Music Engagement Program for people with Alzheimer's disease and dementia: Study protocol for a pilot trialAmelia Gulliver, Georgia Pike, Michelle Banfield, et al.
Molecular Plant-Microbe Interactions : MPMI|April 1, 2014
Single amino acid mutations in the potato immune receptor R3a expand response to Phytophthora effectorsMaría Eugenia Segretin, Marina Pais, Marina Franceschetti, et al.
Plos Pathogens|November 10, 2021
A single amino acid polymorphism in a conserved effector of the multihost blast fungus pathogen expands host-target binding spectrumAdam R Bentham, Yohann Petit-Houdenot, Joe Win, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|December 7, 2023
A method for the efficient evaluation of substrate-based cholinesterase imaging probes for Alzheimer's diseaseSultan Darvesh, Scott Banfield, Maeve Dufour, et al.
Nature Communications|June 23, 2026
Jumbo circular extrachromosomal elements of methane-oxidizing archaea with variably extensive metabolic and defense gene repertoiresLing-Dong Shi, Bethany C Kolody, Shuai Wang, et al.
The ISME Journal|January 6, 2022
Soils and sediments host Thermoplasmata archaea encoding novel copper membrane monooxygenases (CuMMOs)Spencer Diamond, Adi Lavy, Alexander Crits-Christoph, et al.
Human Mutation|March 31, 2012
Inherited deleterious variants in GALNT12 are associated with CRC susceptibilityErica Clarke, Roger C Green, Jane S Green, et al.
Antimicrobial Agents and Chemotherapy|December 20, 2000
Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpointG L Drusano, S L Preston, C Hardalo, et al.
Pageof 118